2006
Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3)
Harris T, Strickler H, Yu H, Pollak M, Monrad E, Travin M, Xue X, Rohan T, Kaplan R. Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3). Growth Hormone & IGF Research 2006, 16: 86-92. PMID: 16530441, DOI: 10.1016/j.ghir.2006.01.002.Peer-Reviewed Original ResearchConceptsFree IGF-I levelsIGF-I levelsInsulin-like growth factorTotal IGFIGFBP-3 levelsFree IGFIGFBP-3Blood specimensBlood collectionEpidemiologic studiesTotal insulin-like growth factorSerum separation tubesGrowth factorRisk of cancerEquation linear regression modelsSerum levelsCardiovascular diseaseMajor binding proteinSerum valuesIGFCommercial assaysIGFBPSpecimen processing timeProtein 3Immunosorbent assay
2004
IGF‐I and breast cancer: A meta‐analysis
Shi R, Yu H, McLarty J, Glass J. IGF‐I and breast cancer: A meta‐analysis. International Journal Of Cancer 2004, 111: 418-423. PMID: 15221971, DOI: 10.1002/ijc.20233.Peer-Reviewed Original ResearchConceptsHedges's standardized mean differenceIGFBP-3 levelsLevels of IGFIGF-binding proteinsBreast cancer riskStandardized mean differencePremenopausal womenBreast cancerIGFBP-3Cancer riskBreast cancer patientsEffects of IGFPostmenopausal womenPostmenopausal groupPremenopausal groupHigher IGFCancer patientsClinical studiesEpidemiologic studiesParacrine mechanismsIGFOverall associationMean differenceCancerWomen
2003
Genotype–phenotype analysis for the polymorphic CA repeat in the insulin-like growth factor-I (IGF-I) gene
Kato I, Eastham J, Li B, Smith M, Yu H. Genotype–phenotype analysis for the polymorphic CA repeat in the insulin-like growth factor-I (IGF-I) gene. European Journal Of Epidemiology 2003, 18: 203-209. PMID: 12800944, DOI: 10.1023/a:1023379100539.Peer-Reviewed Original ResearchConceptsPlasma IGF-I levelsIGF-I levelsInsulin-like growthPlasma IGFHospital-based case-control studyCase-control studyGenotype-phenotype analysisCA repeat lengthInverse associationOverall functional significanceProstate cancerStudy subjectsHealthy individualsChance findingWhite womenIGFRacial subgroupsDirect sequencingPositive associationCancerBlack menNumber of CaFunctional significanceAssociationPolymorphic CA
2002
Insulin Resistance, IGFs and Energy Balance on the Risk of Breast Cancer
Malin A, Zheng W, Yu H. Insulin Resistance, IGFs and Energy Balance on the Risk of Breast Cancer. 2002 DOI: 10.21236/ada406834.Peer-Reviewed Original ResearchShanghai Breast Cancer StudyBreast cancer riskC-peptide levelsBreast cancerC-peptideCancer riskInsulin resistanceBlood C-peptide levelsPre-treatment blood samplesBreast cancer casesSubset of subjectsBreast Cancer StudyIGF bioavailabilityBlood levelsFat distributionPotential joint effectsCancer casesIGF-1Physical activityBlood samplesEpidemiological studiesBody weightIGFCancerGrowth factor
2001
Polymorphic CA repeats in the IGF-I gene and breast cancer
Yu H, Li B, Smith M, Shi R, Berkel H, Kato I. Polymorphic CA repeats in the IGF-I gene and breast cancer. Breast Cancer Research And Treatment 2001, 70: 117-122. PMID: 11768601, DOI: 10.1023/a:1012947027213.Peer-Reviewed Original ResearchConceptsBreast cancer patientsBreast cancerIGF-I geneCancer patientsCA repeatsUnconditional logistic regression analysisInsulin-like growth factorRole of IGFHigher odds ratioLogistic regression analysisHigher plasma IGFIGF-I genotypeBreast cancer cellsIGF-I polymorphismMenopausal statusPeripheral bloodPlasma IGFOdds ratioMedian numberNumber of CaCancerLarger studyAlcohol usePotent mitogenIGFInsulin-like growth factor-I and prostate cancer: a meta-analysis
Shi R, Berkel H, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. British Journal Of Cancer 2001, 85: 991-996. PMID: 11592771, PMCID: PMC2375097, DOI: 10.1054/bjoc.2001.1961.Peer-Reviewed Original ResearchConceptsHedges's standardized mean differenceLevels of IGFProstate cancer patientsStandardized mean differenceIGFBP-3Prostate cancerHigher IGFCancer patientsInsulin-like growth factorIGF-binding proteinsEffects of IGFCase-control studyLow IGFMEDLINE searchIGFMean differenceGrowth factorCancerPatientsStandard protocolRiskLevels
1998
The Acid-Labile Subunit of Human Ternary Insulin-Like Growth Factor Binding Protein Complex in Serum: Hepatosplanchnic Release, Diurnal Variation, Circulating Concentrations in Healthy Subjects, and Diagnostic Use in Patients with Growth Hormone Deficiency
Juul A, Møller S, Mosfeldt-Laursen E, Rasmussen M, Scheike T, Pedersen S, Kastrup K, Yu H, Mistry J, Rasmussen S, Müller J, Henriksen J, Skakkebæk N. The Acid-Labile Subunit of Human Ternary Insulin-Like Growth Factor Binding Protein Complex in Serum: Hepatosplanchnic Release, Diurnal Variation, Circulating Concentrations in Healthy Subjects, and Diagnostic Use in Patients with Growth Hormone Deficiency. The Journal Of Clinical Endocrinology & Metabolism 1998, 83: 4408-4415. PMID: 9851786, DOI: 10.1210/jcem.83.12.5311.Peer-Reviewed Original ResearchConceptsAcid-labile subunitIGFBP-3GH deficiencyALS levelsHepatosplanchnic releaseNormal age-related rangesChildhood-onset GH deficiencyInsulin-like growth factorAge-related rangeSignificant arteriovenous gradientNormal GH responseGH secretory statusConcentrations of IGFLiver vein catheterizationGrowth hormone deficiencyCirculating ConcentrationsGH responseGHD patientsVein catheterizationSecretory statusArteriovenous gradientHormone deficiencyHealthy subjectsDiagnostic utilityIGF